Wednesday, October 19, 2016

Equioxx





Dosage Form: FOR ANIMAL USE ONLY
Equioxx®

Oral Paste for Horses (firocoxib)

Non-steroidal anti-inflammatory drug for oral use in horses only.


CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.



Description


Equioxx® (firocoxib) belongs to the coxib class of non-narcotic, non-steroidal anti-inflammatory drugs. Firocoxib is a white crystalline compound described chemically as 3-(cyclopropylmethoxy)-4-(4-(methylsulfonyl)phenyl)-5,5-dimethylfuranone. The empirical formula is C17H20O5S, and the molecular weight is 336.4. The structural formula is shown below:




Indications


Equioxx Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses.



Dosage and Administration


Always provide the Client Information Sheet with the prescription. The recommended dosage of Equioxx (firocoxib) for oral administration in horses is 0.045 mg/lb (0.1 mg/kg) of body weight once daily for up to14 days. In target animal safety studies, toxicity was seen at the recommended dose when the duration of treatment exceeded 30 days.


Each marking on the syringe will treat 250 pounds of body weight, and each notch corresponds to approximately a 50 lb weight increment. To deliver the correct dose, round the horse's body weight up to the nearest 50 pound increment (if the body weight is an exact 50 pound increment, do not round up). Unlock the knurled ring on the syringe plunger by rotating it ¼ turn. Slide the knurled ring along the plunger shaft so that the side nearest the barrel is at the appropriate 50 lb weight notch. Rotate the plunger ring ¼ turn to lock it in place and ensure it is locked.


Equioxx may be given with or without food.



Contraindications


Horses with hypersensitivity to firocoxib or other NSAIDs should not receive Equioxx Oral Paste.



Warnings


For oral use in horses only. Do not use in horses intended for human consumption.



Human Warnings


Not for use in humans. Keep this and all medications out of the reach of children. Consult a physician in case of accidental ingestion by humans.



Animal Safety


Clients should be advised to observe for signs of potential drug toxicity and be given a Client Information Sheet with each prescription.


For technical assistance or to report suspected adverse events, call 1-877-217-3543.



Precautions


Horses should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests should be conducted to establish hematological and serum biochemical baseline data before and periodically during administration of any NSAID. Clients should be advised to observe for signs of potential drug toxicity and be given a Client Information Sheet with each prescription. See Information for Owner or Person Treating Horse section of this package insert.


Treatment with Equioxx should be terminated if signs such as inappetance, colic, abnormal feces, or lethargy are observed.


As a class, cyclooxygenase inhibitory NSAIDs may be associated with renal and gastrointestinal toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Patients at greatest risk for adverse events are those that are dehydrated, on diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached or avoided. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. Since many NSAIDs possess the potential to produce gastrointestinal ulcerations, concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided or closely monitored. The concomitant use of protein bound drugs with Equioxx Oral Paste has not been studied in horses. The influence of concomitant drugs that may inhibit the metabolism of Equioxx Oral Paste has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy.


The safe use of Equioxx Oral Paste in horses less than one year in age, horses used for breeding, or in pregnant or lactating mares has not been evaluated.


Consider appropriate washout times when switching from one NSAID to another NSAID or corticosteroid.



Adverse Reactions


In controlled field studies, 127 horses (ages 3 to 37 years) were evaluated for safety when given Equioxx Oral Paste at a dose of 0.045 mg/lb (0.1 mg/kg) orally once daily for up to 14 days. The following adverse reactions were observed. Horses may have experienced more than one of the observed adverse reactions during the study.




































Adverse Reactions Seen in U.S. Field Studies
Adverse

Reactions
Equioxx

n=127
Active Control

n=125
Equioxx (firocoxib) Oral Paste was safely used concomitantly with other therapies, including vaccines, anthelmintics, and antibiotics, during the field studies.Abdominal pain01
Diarrhea20 
Excitation10 
Lethargy01 
Loose stool10 
Polydipsia01 
Urticaria01 

Information for Owner or Person Treating Horse


You should give a Client Information Sheet to the person treating the horse and advise them of the potential for adverse reactions and the clinical signs associated with NSAID intolerance. Adverse reactions may include erosions and ulcers of the gums, tongue, lips and face, weight loss, colic, diarrhea, or icterus. Serious adverse reactions associated with this drug class can occur without warning and, in rare situations, result in death. Clients should be advised to discontinue NSAID therapy and contact their veterinarian immediately if any of these signs of intolerance are observed. The majority of patients with drug-related adverse reactions recover when the signs are recognized, drug administration is stopped, and veterinary care is initiated.



Clinical Pharmacokinetics / Pharmacodynamics



Pharmacokinetics


When administered as a 0.045 mg/lb (0.1 mg/kg) dose in oral paste to adult horses with normal access to roughage, feed, and water, the absolute bioavailability of firocoxib from Equioxx paste is approximately 79%. Following oral administration, drug peak concentration (Cmax) of 0.08 mcg/mL can be reached at 4 hours (Tmax) post-dosing. However, in some animals, up to 12 hours may be needed before significant plasma concentrations are observed. Little drug amount distributes into blood cells. The major metabolism mechanism of firocoxib in the horse is decyclopropylmethylation followed by glucuronidation of that metabolite. Based upon radiolabel studies, the majority of label is eliminated in the urine as the decyclopropylmethylated metabolite. Despite a high rate of plasma protein binding (98%), firocoxib exhibits a large volume of distribution (mean Vd(ss) = 1652 mL/kg). The terminal elimination half-life (T½) in plasma averages 30-40 hours after IV or oral paste dosing. Therefore, drug accumulation occurs with repeated dose administrations and steady state concentrations are achieved beyond 6-8 daily oral doses in the horse. Dose linearity exists from 1×-2× of 0.1 mg/kg/day.



Mode of action


Equioxx (firocoxib) is a cyclooxygenase-inhibiting (coxib) class, non-narcotic, non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic activity in animal models.



Effectiveness


Two hundred fifty-three client-owned horses of various breeds, ranging in age from 2 to 37 years and weighing from 595 to 1638 lbs, were randomly administered Equioxx or an active control drug in multi-center field studies. Two hundred forty horses were evaluated for effectiveness and 252 horses were evaluated for safety. Horses were assessed for lameness, pain on manipulation, range of motion, joint swelling, and overall clinical improvement in a non-inferiority evaluation of Equioxx compared to an active control. At study's end, 84.4% of horses treated with Equioxx were judged improved on veterinarians' clinical assessment, and 73.8% were also rated improved by owners. Horses treated with Equioxx showed improvement in veterinarian-assessed lameness, pain on manipulation, range of motion, and joint swelling that was comparable to the active control.



Acceptability


Equioxx Oral Paste was rated both convenient to administer (95.3%) and acceptable to the horse (97.6%) by owners in the multi-center field study.



Animal Safety


In a target animal safety study, firocoxib was administered orally to healthy adult horses (two male castrates and four females per group) at 0, 0.1, 0.3 and 0.5 mg firocoxib/kg body weight (1, 3 and 5× the recommended dose) for 30 days. Administration of firocoxib at 0.3 and 0.5 mg/kg body weight was associated with an increased incidence of oral ulcers as compared to the control group but, no oral ulcers were noted with 0.1 mg/kg. There were no other drug-related adverse findings in this study.


In another target animal safety study, firocoxib was administered orally to healthy adult horses (four males or male castrates and four females per group) at 0, 0.1, 0.3 and 0.5 mg firocoxib/kg body weight (1, 3 and 5× the recommended dose) for 42 days. Administration of firocoxib at 0.1, 0.3 and 0.5 mg/kg body weight was associated with delayed healing of pre-existing oral (lip, tongue, gingival) ulcers. In addition, the incidence of oral ulcers was higher in all treated groups as compared to the control group.


Clinical chemistry and coagulation abnormalities were seen in several horses in the 0.5 mg/kg (5×) group. One 5× male horse developed a mildly elevated BUN and creatinine over the course of the study, prolonged buccal mucosal bleeding time (BMBT), and a dilated pelvis of the right kidney. Another 5× male had a similar mild increase in creatinine during the study but did not have any gross abnormal findings. One female in the 5× group had a prolonged BMBT, bilateral tubulointerstitial nephropathy and bilateral papillary necrosis.


Tubulointerstitial nephropathy occurred in one 3× female, two 3× male horses, and the 5× female horse discussed above with the prolonged BMBT. Papillary necrosis was present in one 1× male horse and the 5× female horse discussed above. Despite the gross and microscopic renal lesions, all of the horses were clinically healthy and had normal hematology, clinical chemistry and urinalysis values.


In another target animal safety study, firocoxib was administered orally to healthy adult horses (three females, two male castrates and one male per group) at 0, 0.25 mg/kg, 0.75 mg/kg and 1.25 mg/kg (2.5, 7.5 and 12.5× the recommended dose of 0.1 mg/kg) for 92 days. An additional group of three females, two male castrates and one male per group, was dosed at 1.25 mg/kg for 92 days but was monitored until Days 147-149. There were treatment-related adverse events in all treated groups. These consisted of ulcers of the lips, gingiva and tongue and erosions of the skin of the mandible and head. Gross and microscopic lesions of the kidneys consistent with tubulointerstitial nephropathy were seen in all treated groups. Papillary necrosis was seen in the 2.5× and 12.5× groups. In addition, several 12.5× horses had elevated liver enzymes (GGT, SDH, AST and ALT). One 2.5× horse had increased urine GGT and urine protein levels which was due to renal hemorrhage and nephropathy. Gastric ulcers of the margo plicatus and glandular area were more prevalent in the 2.5× and 7.5× groups, but not seen in the 12.5× group. The group of horses that were monitored until Days 147-149 showed partial to full recovery from oral and skin ulcers, but no recovery from tubulointerstitial nephropathy.



Storage Information


Store below 86°F (30°C). Brief excursions up to 104°F (40°C) are permitted.



How Supplied


Equioxx is available in packs of 20 individually-boxed syringes and packs of 72 individually wrapped syringes. Each syringe contains 6.93 grams of Equioxx paste, sufficient to treat a 1250 lb. horse.



Marketed by:

Merial LLC, Duluth, GA 30096-4640


Made in Brazil


For technical assistance or to report suspected adverse reactions, call 1-877-217-3543.


NADA 141-253, Approved by FDA


©2009 Merial. All Rights Reserved.


U.S. Pat. No.: 5981576, 6020343


®Equioxx is a registered trademark of Merial.


Rev. 10-09



PATIENT PACKAGE INSERT


Equioxx®

Oral Paste for Horses (firocoxib)


Non-steroidal anti-inflammatory drug


Information for Horse Owners


Equioxx® Oral Paste is administered for up to 14 days for the control of pain and inflammation associated with osteoarthritis in horses.


This summary contains important information about Equioxx. You should read this information before you start giving your horse Equioxx paste and review it each time your prescription is refilled. This sheet is provided only as a summary and does not take the place of instructions from your veterinarian. Talk to your veterinarian if you do not understand any of this information or you want to know more about Equioxx.




 
 

What is Equioxx?


Equioxx is a veterinary prescription non-steroidal anti-inflammatory drug

(NSAID) of the coxib class used to control pain and inflammation associated with osteoarthritis in horses. Osteoarthritis (OA) is a painful condition caused by progressive "wear and tear" of cartilage and other parts of the joints that may result in the following changes or signs in your horse:


  • Limping or lameness.

  • Decreased activity or exercise (reluctance to stand, walk, trot or run, or difficulty in performing these activities).

  • Stiffness or decreased movement of joints.



 
 

How to give Equioxx to your horse.


Equioxx should be given according to your veterinarian's instructions. Do not change the way you give Equioxx to your horse without first speaking with your veterinarian. Do not exceed 14 days of treatment.


The recommended dosage of Equioxx (firocoxib) for oral administration in horses is 0.045 mg/lb (0.1 mg/kg) of body weight once daily for up to 14 days. Each marking on the syringe will treat 250 pounds of body weight, and each notch corresponds to approximately a 50 lb weight increment. To deliver the correct dose, round the horse's body weight up to the nearest 50 pound increment (if the body weight is an exact 50 pound increment, do not round up). Unlock the knurled ring on the syringe plunger by rotating it ¼ turn. Slide the knurled ring along the plunger shaft so that the side nearest the barrel is at the appropriate 50 lb weight notch. Rotate the plunger ring ¼ turn to lock it in place and ensure it is locked.


Equioxx may be given with or without food.




 
 

What kind of results can I expect when my horse is on Equioxx for OA?


While Equioxx is not a cure for osteoarthritis, it can control the pain and

inflammation associated with OA and can improve your horse's mobility.


  • Response varies from horse to horse, but improvement can be quite dramatic.

  • Improvement can be seen in just a few hours in most horses.



 
 

Which horses should not receive Equioxx?


Your horse should not be given Equioxx if he/she:


  • Has an allergic reaction to firocoxib, the active ingredient in Equioxx.

  • Has previously had an allergic reaction (such as hives, facial or lower limb swelling, or red or itchy skin) to aspirin or other NSAIDs.

  • Is presently taking aspirin, phenylbutazone, flunixin meglumine, diclofenac, ketoprofen, or other NSAIDs or corticosteroids.

  • The safety of Equioxx has not been determined in horses less than one year of age or in breeding horses, pregnant or lactating mares.



 
 

Equioxx paste should only be given orally to horses.


  • Equioxx is not for use in horses intended for human food consumption.

  • People should not take Equioxx. Keep Equioxx and all medications out of the reach of children. Consult a physician in case of accidental ingestion by humans.



 
 

What to tell/ask your veterinarian before giving Equioxx.


Talk to your veterinarian about:


  • The signs of OA you have observed in your horse, such as limping or stiffness.

  • If any tests, such as X-rays, will be done before Equioxx is prescribed.

  • How often your horse may need to be examined by your veterinarian.

  • The risks and benefits of using Equioxx.

Tell your veterinarian if your horse has ever had the following medical problems:


  • Any side effects from taking Equioxx or other NSAIDs, such as aspirin or phenylbutazone.

  • Any kidney disease.

  • Any liver disease.

  • Any gastrointestinal ulcers.

Tell your veterinarian about:


  • Other medical problems or allergies that your horse has now, or has had in the past.

  • All medicines that you are giving or plan to give to your horse, including those you can get without a prescription and any dietary supplements.

Tell your veterinarian if you plan to breed your horse, or if your mare is pregnant or nursing a foal.




 
 

What are the possible side effects that may occur in my horse during Equioxx

therapy?


Equioxx, like other NSAIDS, may cause some side effects. Serious side effects associated with NSAID therapy in horses can occur with or without warning. The most common side effects associated with Equioxx therapy involve the tongue, lips and skin of the mouth and face (erosions and ulcers of the mucosa and skin) and the kidney. Gastrointestinal, kidney and liver problems have also been reported with other NSAIDs. Look for the following side effects that may indicate your horse is having a problem with Equioxx or may have another medical problem:


  • Sores or ulcers on the tongue and inside of mouth.

  • Sores, scabs, redness, or rubbing of the facial skin, particularly around the mouth.

  • Change in eating or drinking habits (frequency or amount consumed).

  • Change in urination habits (frequency or color).

  • Yellowing of gums, skin, or whites of the eyes (jaundice).

  • Unexpected weight loss.

  • Change in behavior (such as increased or decreased activity level).

It is important to stop therapy and contact your veterinarian if you think your horse has a medical problem or side effect while taking Equioxx paste. If you have additional questions about possible side effects, talk with your veterinarian or call 1-877-217-3543.




 
 

Can Equioxx be given with other medications?


Equioxx should not be given with other NSAIDs (for example, aspirin, phenylbutazone, diclofenac, ketoprofen or flunixin) or systemic corticosteroids (for example, prednisone, cortisone, dexamethasone, or triamcinolone).


Tell your veterinarian about all medications that you have given your horse in the past, and any medications you are planning to give with Equioxx paste. This should include other medicines that you can get without a prescription or any dietary supplements. Your veterinarian may want to check that all of your horse's medicines can be given together.




 
 

What do I do in case my horse receives more than the prescribed amount of Equioxx?


  • Consult your veterinarian if your horse receives more than the prescribed

    amount of Equioxx.



 
 

What else should I know about Equioxx?


  • This sheet provides a summary of information about Equioxx paste and general information about NSAIDs. If you have any questions or concerns about Equioxx or osteoarthritis pain, talk with your veterinarian.

  • As with all prescribed medicines, Equioxx paste should only be given to the horse for which it is prescribed. It should be given to your horse only for the condition for which it is prescribed, at the labeled dose and duration.

  • It is important to periodically discuss your horse's response to Equioxx paste. Your veterinarian will determine if your horse is responding as expected and if your horse should continue receiving Equioxx paste.


PRINCIPAL DISPLAY PANEL - 6.93 g Syringe Carton


[NADA 141-253,

Approved by FDA]


Equioxx®

(firocoxib)


Non-steroidal

anti-inflammatory

for the control of pain

and inflammation associated

with osteoarthritis in horses.


Net Wt. 6.93 g


Oral Paste for Horses


Caution: Federal law restricts

this drug to use by or on the

order of a licensed veterinarian.










Equioxx 
firocoxib  paste










Product Information
Product TypePRESCRIPTION ANIMAL DRUGNDC Product Code (Source)50604-6597
Route of AdministrationORALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
firocoxib (firocoxib)firocoxib8.2 mg  in 1 g





Inactive Ingredients
Ingredient NameStrength
No Inactive Ingredients Found


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      






















Packaging
#NDCPackage DescriptionMultilevel Packaging
150604-6597-11 SYRINGE In 1 CARTONcontains a SYRINGE, PLASTIC
16.93 g In 1 SYRINGE, PLASTICThis package is contained within the CARTON (50604-6597-1)
250604-6597-272 SYRINGE In 1 CARTONcontains a SYRINGE, PLASTIC
26.93 g In 1 SYRINGE, PLASTICThis package is contained within the CARTON (50604-6597-2)










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NADANADA14125312/30/2005


Labeler - Merial Limited (034393582)
Revised: 06/2010Merial Limited

Pseudoephedrine/Naproxen


Pronunciation: SOO-doe-e-FED-rin/na-PROX-en
Generic Name: Pseudoephedrine/Naproxen
Brand Name: Examples include Aleve Cold and Sinus and Sudafed Pressure + Pain 12 Hour

Pseudoephedrine/Naproxen contains a nonsteroidal anti-inflammatory drug (NSAID). It may cause an increased risk of serious and sometimes fatal heart and blood vessel problems (eg, a heart attack, a stroke). The risk may be greater if you already have heart problems or if you take Pseudoephedrine/Naproxen for a long time. Do not use Pseudoephedrine/Naproxen right before or after bypass heart surgery.


Pseudoephedrine/Naproxen may cause an increased risk of serious and sometimes fatal stomach ulcers and bleeding. Elderly patients may be at greater risk. This may occur without warning signs.





Pseudoephedrine/Naproxen is used for:

Temporarily relieving symptoms, such as sinus pressure, minor body aches and pain, headache, fever, and nasal and sinus congestion, due to colds, sinus problems, and flu. It may also be used for other conditions as determined by your doctor.


Pseudoephedrine/Naproxen is an NSAID and decongestant combination. The NSAID works in the brain to help decrease pain. The decongestant works by constricting blood vessels and reducing swelling in the nasal passages, which relieves congestion and pressure.


Do NOT use Pseudoephedrine/Naproxen if:


  • you are allergic to any ingredient in Pseudoephedrine/Naproxen

  • you have had a severe allergic reaction (eg, severe rash, hives, trouble breathing, growths in the nose, dizziness) to aspirin or an NSAID (eg, celecoxib, ibuprofen)

  • you have recently had or will be having bypass heart surgery

  • you have severe high blood pressure, severe heart blood vessel disease, a rapid heartbeat, or severe heart problems

  • you are taking furazolidone or have taken a monoamine oxidase inhibitor (MAOI) (eg, phenelzine) within the last 14 days

  • you are in the last 3 months of pregnancy

  • you are taking another medicine that contains naproxen

Contact your doctor or health care provider right away if any of these apply to you.



Before using Pseudoephedrine/Naproxen:


Some medical conditions may interact with Pseudoephedrine/Naproxen. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have a history of adrenal gland problems (eg, an adrenal gland tumor), stomach or bowel problems (eg, bleeding, perforation, ulcers, persistent or returning stomach pain or heartburn), diabetes, glaucoma or increased eye pressure, an enlarged prostate or other prostate problems, seizures, thyroid problems, kidney problems, or liver problems

  • if you have high blood pressure, blood disorders, bleeding or clotting problems, heart problems (eg, heart failure, irregular heartbeat), a blood vessel disease (eg, arteriosclerosis), or if you are at risk of any of these diseases

  • if you have a history of swelling or fluid buildup, lupus, asthma, growths in the nose (nasal polyps), or mouth inflammation

  • if you have poor health, dehydration or low fluid volume, or low blood sodium levels; you are on a low-salt (sodium) diet; you drink alcohol; you smoke; or you have a history of alcohol abuse

  • if you are taking medicine for high blood pressure

Some MEDICINES MAY INTERACT with Pseudoephedrine/Naproxen. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Anticoagulants (eg, warfarin), antiplatelet medicines (eg, clopidogrel, prasugrel), aspirin, corticosteroids (eg, prednisone), factor Xa inhibitors (eg, enoxaparin), heparin, or selective serotonin reuptake inhibitors (SSRIs) (eg, fluoxetine), or other NSAIDs (eg, ibuprofen) because the risk of stomach bleeding may be increased

  • Digoxin, furazolidone, linezolid, MAOIs (eg, phenelzine), probenecid, tricyclic antidepressants (eg, amitriptyline), or urinary alkalinizers (eg, sodium bicarbonate) because they may increase the risk of Pseudoephedrine/Naproxen's side effects

  • Bisphosphonates (eg, alendronate), bromocriptine, cyclosporine, droxidopa, hydantoins (eg, phenytoin), lithium, methotrexate, quinolones (eg, ciprofloxacin), sulfonamides (eg, sulfamethoxazole), or sulfonylureas (eg, glipizide) because the risk of their side effects may be increased by Pseudoephedrine/Naproxen

  • Angiotensin-converting enzyme (ACE) inhibitors (eg, enalapril), beta-blockers (eg, propranolol), diuretics (eg, furosemide, hydrochlorothiazide), guanadrel, guanethidine, mecamylamine, methyldopa, or reserpine because their effectiveness may be decreased by Pseudoephedrine/Naproxen

This may not be a complete list of all interactions that may occur. Ask your health care provider if Pseudoephedrine/Naproxen may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Pseudoephedrine/Naproxen:


Use Pseudoephedrine/Naproxen as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Pseudoephedrine/Naproxen by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation. Taking it with food may not lower the risk of stomach or bowel problems (eg, bleeding, ulcers). Talk with your doctor or pharmacist if you have persistent stomach upset.

  • Take Pseudoephedrine/Naproxen with a full glass of water (8 oz/240 mL) as directed by your doctor.

  • Swallow Pseudoephedrine/Naproxen whole. Do not break, crush, or chew before swallowing.

  • If you take antacids, cholestyramine, or sucralfate, ask your doctor or pharmacist how to take them with Pseudoephedrine/Naproxen.

  • If you miss a dose of Pseudoephedrine/Naproxen and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Pseudoephedrine/Naproxen.



Important safety information:


  • Pseudoephedrine/Naproxen may cause drowsiness or dizziness. These effects may be worse if you take it with alcohol or certain medicines. Use Pseudoephedrine/Naproxen with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Serious stomach ulcers or bleeding can occur with the use of Pseudoephedrine/Naproxen. Taking it in high doses or for a long time, smoking, or drinking alcohol increases the risk of these side effects. Taking Pseudoephedrine/Naproxen with food will NOT reduce the risk of these effects. Contact your doctor or emergency room at once if you develop severe stomach or back pain; black, tarry stools; vomit that looks like blood or coffee grounds; or unusual weight gain or swelling.

  • Talk to your doctor before you take Pseudoephedrine/Naproxen if you drink more than 3 drinks with alcohol per day.

  • Do not take diet or appetite control medicines while you are taking Pseudoephedrine/Naproxen without checking with you doctor.

  • Pseudoephedrine/Naproxen has naproxen and pseudoephedrine in it. Before you start any new medicine, check the label to see if it has naproxen, any other NSAID (eg, ibuprofen), pseudoephedrine, or another decongestant in it too. If it does or if you are not sure, check with your doctor or pharmacist.

  • Do NOT take more than the recommended dose or use for longer than directed without checking with your doctor.

  • Contact your doctor if you have trouble swallowing, severe or persistent heartburn, or if it feels like the tablet is stuck in your throat.

  • If your congestion does not get better within 7 days or you have a fever that does not get better within 3 days, check with your doctor. If your symptoms get worse or if you have new symptoms, check with your doctor.

  • Tell your doctor or dentist that you take Pseudoephedrine/Naproxen before you receive any medical or dental care, emergency care, or surgery.

  • Do not take aspirin while you are taking Pseudoephedrine/Naproxen unless your doctor tells you to.

  • Pseudoephedrine/Naproxen may interfere with certain lab tests. Be sure your doctor and lab personnel know that you take Pseudoephedrine/Naproxen.

  • Diabetes patients - Pseudoephedrine/Naproxen may affect your blood sugar. Check blood sugar levels closely and ask your doctor before adjusting the dose of your diabetes medicine.

  • Use Pseudoephedrine/Naproxen with caution in the ELDERLY; they may be more sensitive to its effects, especially stomach bleeding and kidney problems.

  • Pseudoephedrine/Naproxen should not be used in CHILDREN younger than 12 years old without first checking with the child's doctor; safety and effectiveness in these children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: Pseudoephedrine/Naproxen may cause harm to the fetus. Do not take Pseudoephedrine/Naproxen during the last 3 months of pregnancy. If you think you may be pregnant, contact your doctor. You will need to discuss the benefits and risks of taking Pseudoephedrine/Naproxen while you are pregnant. Pseudoephedrine/Naproxen should not be taken during labor. Pseudoephedrine/Naproxen is found in breast milk. Do not breast-feed while taking Pseudoephedrine/Naproxen.


Possible side effects of Pseudoephedrine/Naproxen:


All medicines may cause side effects, but many people have no, or minor side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Constipation; diarrhea; dizziness; drowsiness; excitability; gas; headache; heartburn; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; wheezing); bloody or black, tarry stools; change in the amount of urine produced; chest pain; confusion; dark urine; depression; fainting; fast or irregular heartbeat; fever, chills, or persistent sore throat; hallucinations; loss of appetite; mood or mental changes; numbness of an arm or leg; one-sided weakness; pale stools; persistent trouble sleeping; red, swollen, blistered, or peeling skin; restlessness; ringing in the ears; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; severe or persistent stomach pain or nausea; severe vomiting; shortness of breath; sudden or unexplained weight gain; swelling of the hands, legs, or feet; tremor; unusual bruising or bleeding; unusual joint or muscle pain; unusual tiredness or weakness; vision or speech changes; vomit that looks like coffee grounds; yellowing of skin or eyes.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.



If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; decreased urination; hallucinations; loss of consciousness; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; severe nausea or stomach pain; slow or troubled breathing; unusual bleeding or bruising; unusually fast, slow, or irregular heartbeat; vomit that looks like coffee grounds.


Proper storage of Pseudoephedrine/Naproxen:

Store Pseudoephedrine/Naproxen at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Pseudoephedrine/Naproxen out of the reach of children and away from pets.


General information:


  • If you have any questions about Pseudoephedrine/Naproxen, please talk with your doctor, pharmacist, or other health care provider.

  • Pseudoephedrine/Naproxen is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Pseudoephedrine/Naproxen. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Pseudoephedrine/Naproxen resources


  • Pseudoephedrine/Naproxen Use in Pregnancy & Breastfeeding
  • Pseudoephedrine/Naproxen Drug Interactions
  • Pseudoephedrine/Naproxen Support Group
  • 1 Review for Pseudoephedrine/Naproxen - Add your own review/rating


Compare Pseudoephedrine/Naproxen with other medications


  • Nasal Congestion
  • Pain/Fever
  • Sinus Symptoms

Tuesday, October 18, 2016

ProstaScint





Dosage Form: injection, suspension
ProstaScint® Kit

(capromab pendetide)


Kit for the Preparation of Indium In 111 Capromab Pendetide

For Intravenous Use Only

DESCRIPTION


ProstaScint® (capromab pendetide) is the murine monoclonal antibody, 7E11-C5.3, conjugated to the linker-chelator, glycyl-tyrosyl-(N, ε-diethylenetriaminepentaacetic acid)-lysine hydrochloride (GYK-DTPA-HCl). The 7E11-C5.3 antibody is of the IgG1, kappa subclass (IgG1κ). This antibody is directed against a glycoprotein expressed by prostate epithelium known as Prostate Specific Membrane Antigen (PSMA). The PSMA epitope recognized by monoclonal antibody (MAb) 7E11-C5.3 is located in the cytoplasmic domain. Expression of this glycoprotein has not been demonstrated on any other adenocarcinomas or transitional cell cancers tested. The antibody is produced by serum-free in vitro cultivation of cells, and purified by sequential protein isolation and chromatographic separation procedures.


Each ProstaScint® kit consists of two vials which contain all of the non-radioactive ingredients necessary to produce a single unit dose of Indium In 111 ProstaScint®, an immunoscintigraphic agent for administration by intravenous injection only. The ProstaScint® vial contains 0.5 mg of capromab pendetide in 1 mL of sodium phosphate buffered saline solution adjusted to pH 6; a sterile, pyrogen-free, clear, colorless solution that may contain some translucent particles. The vial of sodium acetate buffer contains 82 mg of sodium acetate in 2 mL of Water for Injection adjusted to pH 5-7 with glacial acetic acid; it is a sterile, pyrogen-free, clear, and colorless solution. Neither solution contains a preservative. Each kit also includes one sterile 0.22 μm Millex® GV filter, prescribing information, and two identification labels.


The sodium acetate solution must be added to the sterile, non-pyrogenic high purity Indium In 111 Chloride solution to buffer it prior to radiolabeling ProstaScint®. The immunoscintigraphic agent Indium In 111 Capromab Pendetide (Indium In 111 ProstaScint®) is formed after radiolabeling with Indium In 111.



Physical Characteristics of Indium In 111


Indium In 111 decays by electron capture with a physical half-life of 67.2 hours (2.8 days).1 The energies of the photons that are useful for detection and imaging studies are listed in TABLE 1.












TABLE 1 - INDIUM IN 111 PRINCIPAL

RADIATION EMISSION DATA1
RadiationMean % per

Disintegration
Mean

Energy (keV)
Gamma 290.2171.3
Gamma 394245.4

External Radiation


The exposure rate constant for 37 MBq (1 mCi) of Indium In 111 is 8.3 x 10-4 C/kg/hr (3.21 R/hr). The first half-value thickness of lead (Pb) for Indium In 111 is 0.023 cm. A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from the interposition of various thicknesses of Pb is shown in TABLE 2. For example, the use of 0.834 cm of lead will decrease the external radiation exposure by a factor of about 1,000.















TABLE 2 - INDIUM IN 111 RADIATION

ATTENUATION OF LEAD SHIELDING2
Shield Thickness

(Pb) cm
Attenuation Factor
0.0230.5
0.20310-1
0.51310-2
0.83410-3
1.12010-4

These estimates of attenuation do not take into consideration the presence of longer-lived contaminants with higher energy photons, namely Indium In 114m/114.


To allow correction for physical decay of Indium In 111, the fractions that remain at selected intervals before and after the time of calibration are shown in TABLE 3.








































TABLE 3 - INDIUM IN 111

PHYSICAL DECAY CHART, HALF-LIFE

67.2 HOURS (2.8 DAYS)
* Calibration Time
HoursFraction

Remaining
-481.64
-361.44
-241.28
-121.13
0*1.00
120.88
240.78
360.69
480.61
600.54
720.48
840.42
960.37
1080.33
1200.29
1320.26
1440.23

CLINICAL PHARMACOLOGY



Pharmacodynamics


Prostate Specific Membrane Antigen is expressed in many primary and metastatic prostate cancer lesions, and in vitro immunohistologic studies have shown 7E11-C5.3 to be reactive with > 95% of the prostate adenocarcinomas evaluated. In general, PSMA expression by prostate cancer cells is either unchanged or increased in patients treated with hormonal therapy (see PRECAUTIONS, Drug Interactions). The 7E11-C5.3 antibody is immunoreactive with normal and hypertrophic adult prostate tissue. In clinical studies of patients with prostate cancer, Indium In 111 ProstaScint® (capromab pendetide) localized to the prostate, and some known primary and metastatic tumor sites.


Non-antigen-dependent localization, suspected to be secondary to catabolism, has been observed in the liver, spleen, and bone marrow. Although there is variation among individuals, there may also be localization and imaging activity in the bowel, blood pool, kidneys, urinary bladder, and genitalia. Intracellular localization of 7E11-C5.3 has been observed in histochemically prepared tissue sections from normal adult skeletal and cardiac muscle, although primate studies revealed no specific localization to these tissues.



Pharmacokinetics


Based on data obtained from clinical studies, Indium In 111 ProstaScint® demonstrated a monoexponential elimination pattern with a terminal-phase half life of 67 ± 11 hours (mean ± SD). Approximately 10% of the administered radioisotope dose is excreted in the urine during the 72 hours following intravenous infusion. The pharmacokinetics of Indium In 111 ProstaScint® are characterized by slow serum clearance rate (42 ± 22 mL/hr) and small volume of distribution (4 ± 2.1 L).



CLINICAL STUDIES


Indium In 111 ProstaScint® (capromab pendetide) has been administered in single doses to over 600 patients in clinical studies, and in repeat administrations (2 to 4 infusions) to 61 patients. A 0.5 mg dose was determined to be the lowest effective dose. The imaging performance of Indium In 111 ProstaScint® (capromab pendetide) was evaluated in a phase 2 and a phase 3 trial in each of two clinical settings: (1) patients with clinically-localized prostate cancer who were at high risk for metastases and (2) patients with a high clinical suspicion for occult recurrent or residual prostate cancer.



Imaging Performance in Newly-Diagnosed Patients


In one of two open label, multi-center, uncontrolled pivotal phase 3 trials, 160 patients with a tissue diagnosis of prostate cancer who were considered at high risk for lymph node metastases underwent Indium In 111 ProstaScint® immunoscintigraphy prior to scheduled staging pelvic lymphadenectomy. High risk was defined as at least one of the following: (1) prostate specific antigen (PSA) ≥10x the upper limit of normal & Gleason score ≥7; (2) prostatic acid phosphatase above the upper limit of normal; (3) equivocal evidence of lymph node metastases on CT or ultrasound & PSA ≥8x the upper limit of normal; (4) Gleason score ≥8; or (5) clinical stage C & Gleason score ≥6. All patients had been evaluated for metastatic disease using standard non-invasive imaging techniques, and were considered to have clinically-localized prostate cancer. The Indium In 111 ProstaScint® images were interpreted on-site, and the reader had access to all clinical data. The interpretations were correlated with the results of surgical staging; however, a correlation of specific areas of Indium In 111 ProstaScint® uptake to specific sites of tumor involvement was not performed.


One hundred fifty-two patients had an interpretable scan and surgical staging. Forty scans were classified as true positive, 25 as false positive, 63 as true negative, and 24 as false negative. The results for immunoscintigraphy are summarized in TABLE 4.

























TABLE 4 - COMPARISON OF INDIUM

IN 111 ProstaScint® AND

HISTOPATHOLOGIC RESULTS FOR

PRESURGICAL PATIENTS
Number of Patients
Indium In 111 ProstaScint®
+-
Biopsy +4024Sensitivity =

62%
Biopsy -2563Specificity =

72%
Positive

Predictive

Value

62%
Negative

Predictive

Value

72%
Overall

Accuracy

68%

Sixty-five patients (43%) had positive Indium In 111 ProstaScint® images for pelvic lymph node metastases: Of these 38% (25 patients) did not have metastatic prostate cancer at surgery. Eighty-seven patients (57%) had negative Indium In 111 ProstaScint® images: Of these 28% (24 patients) did have metastatic prostate cancer at surgery. The overall accuracy of Indium In 111 ProstaScint® immunoscintigraphy, as measured against pelvic lymph node dissection, was 68% (103/152).


A retrospective subset analysis suggested that a positive Indium In 111 ProstaScint® scan in patients with a Gleason score ≥ 7 and a PSA ≥ 40 contained additional information regarding the likelihood that tumor metastases would be found at the scheduled staging pelvic lymphadenectomy.



Imaging Performance in Patients with Occult Recurrent or Residual Disease


In the second open label, multi-center, uncontrolled pivotal phase 3 trial, 183 patients with a high clinical suspicion of residual or recurrent prostate cancer following radical prostatectomy were evaluated. Patients with a rising PSA, a negative bone scan, and negative or equivocal standard diagnostic techniques, (e.g. transrectal ultrasound, CT scan, or MRI) underwent Indium In 111 ProstaScint® immunoscintigraphy prior to biopsy of the prostatic fossa. The Indium In 111 ProstaScint® images were interpreted on-site, and the reader had access to all clinical data. The interpretations were correlated with the results of histopathologic analysis of the prostatic fossa biopsy specimens.


One hundred fifty-eight patients had an interpretable scan and prostatic fossa biopsy. Twenty-nine scans were classified as true positive, 29 as false positive, 70 as true negative, and 30 as false negative. The results are summarized in TABLE 5.

























TABLE 5 - INDIUM IN 111 ProstaScint®

AND HISTOPATHOLOGIC RESULTS

FOR RECURRENT OR RESIDUAL

DISEASE PATIENTS
Number of Patients
Indium In 111 ProstaScint®
+-
Biopsy +2930Sensitivity

49%
Biopsy -2970Specificity

71%
Positive

Predictive

Value

50%
Negative

Predictive

Value

70%
Overall

Accuracy

63%

Fifty-eight patients (37%) had positive Indium In 111 ProstaScint® images in the prostatic fossa: Of these 50% (29 patients) did not have recurrent prostate cancer on biopsy. One hundred patients (63%) had negative Indium In 111 ProstaScint® images: Of these 30% (30 patients) had recurrent prostate cancer on biopsy. The overall accuracy of Indium In 111 ProstaScint® immunoscintigraphy, as measured against prostatic fossa biopsy, was 63% (99/158).


Indium In 111 ProstaScint® localized to only the prostatic fossa in 29 (18%) patients, to prostatic fossa and extrafossa sites in 29 (18%) patients, and to only extrafossa sites in 39 (25%) patients. The study was not designed to evaluate extrafossa sites of uptake. Three extrafossa sites of uptake were biopsied, one of which was positive for metastatic prostate cancer.



ProstaScint® Results in Patients with Distant Metastases


Clinical trials have not specifically studied the ability of Indium In 111 ProstaScint® (capromab pendetide) to image distant (extra-pelvic) metastases, and a limited number of patients with distant (primarily bone) metastases were enrolled. Thirteen patients out of 16 (81%) with CT evidence of distant soft tissue disease had positive extrafossa Indium In 111 ProstaScint® scans. Thirty-five out of 61 patients (57%) with bone scan evidence of disease had positive Indium In 111 ProstaScint® skeletal uptake; however, Indium In 111 ProstaScint® imaging did not identify most sites of abnormal bone uptake on bone scan, nor did it demonstrate any new sites of metastasis that were not seen on bone scan. The Indium In 111 ProstaScint® scan did, however, demonstrate sites of bone marrow metastases that were not seen on bone scan in 2 of 43 patients in the phase 1 study.



Repeat Scans


Sixty-one patients received a total of 74 repeat infusions of Indium In 111 ProstaScint®. The incidence of adverse reactions upon repeat infusion (5%) was comparable to that observed after single infusion (4%). Human anti-mouse antibody (HAMA) levels were detected (at levels >8 ng/mL) by radioimmune assay (RIA) after single infusion in 8% (20/239) of patients while 1% of patients had levels greater than 100 ng/mL. Serum HAMA levels were detected by RIA after repeat infusion in 19% (5/27) of patients.


Biodistribution was unaltered on 65 of 70 (93%) evaluable repeat scans. The efficacy of repeat Indium In 111 ProstaScint® imaging was not evaluated.



INDICATIONS AND USAGE


Indium In 111 ProstaScint® (capromab pendetide) is indicated as a diagnostic imaging agent in newly-diagnosed patients with biopsy-proven prostate cancer, thought to be clinically-localized after standard diagnostic evaluation (e.g. chest x-ray, bone scan, CT scan, or MRI), who are at high-risk for pelvic lymph node metastases (see CLINICAL PHARMACOLOGY, Imaging Performance in Newly-Diagnosed Patients). It is not indicated in patients who are not at high risk.


Indium In 111 ProstaScint® is also indicated as a diagnostic imaging agent in post-prostatectomy patients with a rising PSA and a negative or equivocal standard metastatic evaluation in whom there is a high clinical suspicion of occult metastatic disease. The imaging performance of Indium In 111 ProstaScint® following radiation therapy has not been studied.


The information provided by Indium In 111 ProstaScint® imaging should be considered in conjunction with other diagnostic information. Scans that are positive for metastatic disease should be confirmed histologically in patients who are otherwise candidates for surgery or radiation therapy unless medically contraindicated. Scans that are negative for metastatic disease should not be used in lieu of histological confirmation.


ProstaScint® is not indicated as a screening tool for carcinoma of the prostate nor for readministration for the purpose of assessment of response to treatment.



CONTRAINDICATIONS


Indium In 111 ProstaScint® (capromab pendetide) should not be used in patients who are hypersensitive to this or any other product of murine origin or to Indium In 111 chloride.



WARNINGS


Patient management should not be based on Indium In 111 ProstaScint® (capromab pendetide) scan results without appropriate confirmatory studies since in the pivotal trials, there was a high rate of false positive and false negative image interpretations (See PRECAUTIONS).


Indium In 111 ProstaScint® images should be interpreted only by physicians who have had specific training in Indium In 111 ProstaScint® image interpretation (see PRECAUTIONS, Imaging Precautions).


Allergic reactions, including anaphylaxis, can occur in patients who receive murine antibodies. Although serious reactions of this type have not been observed in clinical trials after Indium In 111 ProstaScint® administration, medications for the treatment of hypersensitivity reactions should be available during administration of this agent.


Indium In 111 ProstaScint® may induce human anti-mouse antibodies which may interfere with some immunoassays, including those used to assay PSA and digoxin (see PRECAUTIONS, Drug/Laboratory Test Interactions).



PRECAUTIONS



General


There were high rates of false positive and false negative image interpretations in the pivotal trials (see Clinical Studies). False positive scan interpretations may result in: (1) inappropriate surgical intervention to confirm scan results; (2) inappropriate denial of curative therapy if results are not confirmed; or (3) inadequate surgical staging if only areas of uptake are sampled. Surgical sampling should not be limited to the areas of positive uptake, unless histologic examination of these areas is diagnostic. Due to the potential for false negative scan interpretations, negative images should not be used in lieu of histologic confirmation. Proper patient preparation is mandatory to obtain optimal images for interpretation (see Imaging Precautions, below).


Bone scans are more sensitive than ProstaScint® (capromab pendetide) for the detection of metastases to bone, and Indium In 111 ProstaScint® should not replace bone scan for the evaluation of skeletal metastases.



Imaging Precautions


Radiopharmaceuticals should be used only by physicians and other professionals who are qualified by training and experience in the safe use and handling of radionuclides. Indium In 111 ProstaScint® images should be interpreted only by physicians who have had specific training in the interpretation of Indium In 111 ProstaScint® images.


There may be Indium In 111 ProstaScint® clearance and imaging localization observed in the bowel, blood pool, kidneys, and urinary bladder. When obtaining all 72-120 hour planar and Single-Photon Emission Computed Tomography (SPECT) images, the bladder should be catheterized and irrigated. The administration of a cathartic is required the evening before imaging the patient, and a cleansing enema should be administered within an hour prior to each 72-120 hour imaging session.


The contents of the kit are not radioactive. However, after the Indium In 111 chloride is added, appropriate shielding of Indium In 111 ProstaScint® must be maintained. Care should be taken to minimize radiation exposure to patients and medical personnel, consistent with proper hospital and patient management procedures.


Each ProstaScint® kit is a unit of use package. The contents of the kit are to be used only to prepare Indium In 111 ProstaScint® -- unlabeled ProstaScint® should NOT be administered directly to the patient. After radiolabeling with Indium In 111, the entire Indium In 111 ProstaScint® dose must be administered to the patient for whom it was prescribed. Reducing the dose of Indium In 111, unlabeled ProstaScint®, or Indium In 111 ProstaScint® may adversely impact imaging results and is not recommended.


The components of the kit are sterile and pyrogen-free and contain no preservative. Indium In 111 ProstaScint® should be used within 8 hours after radiolabeling. It is essential to follow the directions for preparation carefully and to adhere to strict aseptic procedures during preparation of the radiolabeled product.



Information for Patients


Murine monoclonal antibodies (MAbs) are foreign proteins, and their administration can induce HAMA. While limited data exist concerning the clinical significance of HAMA, the presence of HAMA may interfere with murine-antibody based immunoassays, or could compromise the efficacy of diagnostic or therapeutic murine antibody-based agents and increase the risk of adverse reactions. For these reasons, patients should be informed that the use of this product could adversely affect the future ability to diagnose recurrence of their tumor, the ability to perform certain other laboratory tests, or to use other murine-based products. Patients should be advised to discuss prior use of murine-antibody based products with their physicians (see Heterologous Protein Administration, below).



Heterologous Protein Administration


Indium In 111 ProstaScint® (capromab penditide) has been shown to induce HAMA to murine IgG infrequently and with low peak levels after single administration. HAMA levels were detected (at >8 ng/mL) by RIA after single infusion in 8% (20/239) of patients, while 1% of patients had levels greater than 100 ng/mL. In addition, serum HAMA levels were detected by RIA after repeat infusion in 19% (5/27) of the patients.


While limited data exist concerning the clinical significance of HAMA, detectable serum levels can alter the clearance and tissue biodistribution of MAbs. The development of persistently elevated serum HAMA levels could compromise the efficacy of diagnostic or therapeutic murine antibody-based agents. In repeat administration trials, 93% (65/70) of the evaluable repeat infusions were associated with normal tissue distribution of the MAb conjugate. Pre-infusion serum HAMA levels were generally not predictive of altered distribution.


When considering the administration of Indium In 111 ProstaScint® to patients who have previously received other murine antibody-based products, physicians should be aware of the potential for assay interference and increased clearance and altered biodistribution, which may interfere with the quality or sensitivity of the imaging study. Prior to administration of murine antibodies, including Indium In 111 ProstaScint®, the physician should review the patient history to determine whether the patient has previously received such products.



Drug Interactions


The effect of surgical and/or medical androgen ablation on the imaging performance of Indium In 111 ProstaScint® has not been studied. Preliminary data suggest hormone ablation may increase PSMA expression, with concurrent decrease in tumor expression of PSA.3 The use of ProstaScint® in this patient population cannot be recommended at this time.



Drug/Laboratory Test Interactions


The presence of HAMA in serum as a result of ProstaScint® may interfere with some antibody-based immunoassays (such as PSA and digoxin). When present, this interference generally results in falsely high values. When following PSA levels, assay methods resistant to HAMA interference should be utilized. PSA assays which were found to be resistant to HAMA interference were Hybritech Tandem-R and Abbott IMX.


When patients have received Indium In 111 ProstaScint®, the clinical laboratory should be notified to take appropriate measures to avoid interference by HAMA with clinical laboratory testing procedures. These methods include the use of non-murine-based immunoassays, HAMA removal by adsorption, or sample pre-treatment to block HAMA activity.



Carcinogenesis, Mutagenesis, Impairment of Fertility


Long-term animal studies have not been performed to evaluate the carcinogenic or mutagenic potential of Indium In 111 ProstaScint® or to evaluate its effect on fertility.



Pregnancy


ProstaScint® is not indicated for use in women.



Pediatric Use


The safety and effectiveness of Indium In 111 ProstaScint® in pediatric patients have not been established. ProstaScint® is not indicated for use in children.



ADVERSE REACTIONS


ProstaScint® (capromab pendetide) was generally well tolerated in the clinical trials. After administration of 529 single doses of Indium In 111 ProstaScint®, adverse reactions were observed in 4% of patients. The most commonly reported adverse reactions were increases in bilirubin, hypotension, and hypertension, which occurred in 1% of patients. Elevated liver enzymes and injection site reactions occurred in slightly less than 1% of patients. Other adverse reactions, listed in order of decreasing frequency, were: pruritus, fever, rash, headache, myalgia, asthenia, burning sensation in thigh, shortness of breath, and alteration of taste. Most adverse reactions were mild and readily reversible. Data from repeat administration in 61 patients revealed a similar incidence of adverse reactions (5%). No deaths were attributable to Indium In 111 ProstaScint® administration.



OVERDOSAGE


The maximum amount of Indium In 111 ProstaScint® (capromab pendetide) that can be safely administered has not been determined. In clinical studies, single doses of 10 mg of Indium In 111 ProstaScint® were administered to 20 patients with prostate cancer; the type and frequency of adverse reactions at this dose were similar to those observed with lower doses. The maximum Indium In 111 dose administered with ProstaScint® in a clinical study was 6.5 mCi.



DOSAGE AND ADMINISTRATION


The patient dose of the radiolabel must be measured in a dose calibrator prior to administration.


The recommended dose of ProstaScint® (capromab pendetide) is 0.5 mg radiolabeled with 5 mCi of Indium In 111 chloride. Each dose is administered intravenously over 5 minutes and should not be mixed with any other medication during its administration. Indium In 111 ProstaScint® may be readministered following infiltration or a technically inadequate scan; however, it is not indicated for readministration for the purpose of assessment of response to treatment (see INDICATIONS AND USAGE).


Each ProstaScint® kit is a unit dose package. After radiolabeling with Indium In 111, the entire Indium In 111 ProstaScint® dose should be administered to the patient. Reducing the dose of Indium In 111, unlabeled ProstaScint®, or Indium In 111 ProstaScint® may adversely impact imaging results and is, therefore, not recommended. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.



Radiation Dosimetry


The estimated absorbed radiation doses to an average adult patient from an intravenous injection of ProstaScint® labeled with 5 mCi of Indium In 111 are shown in TABLE 6. Total dose estimates include absorbed radiation doses from both Indium In 111 and the Indium In 114m radiocontaminant. A level of 0.06% of Indium In 114m was utilized for the dose estimates presented in TABLE 6.












































































TABLE 6 - ESTIMATED AVERAGE

ABSORBED RADIATION DOSE

IN ADULT PATIENTS FROM INTRAVENOUS

ADMINISTRATION OF ProstaScint®

LABELED WITH 5 mCi (185 MBq) OF

INDIUM IN 111 CHLORIDEa
a Based on data from 21 patients who received doses of ProstaScint® labeled with a mean (± SD) Indium In 111 dose of 4.6 ± 1.0 mCi.
OrganAverage

Dose

(rad/5 mCi)
Average

Dose

(mGy/185 MBq)
Total body2.727
Brain1.111
Liver18.5185
Spleen16.3163
Kidneys12.4124
Lungs5.656
Heart wall7.878
Red marrow4.343
Adrenals5.252
Urine Bladder wall2.222
Bone Surfaces4.040
Stomach3.131
Gall Bladder Wall7.373
Small Intestine3.333
Upper Large Intestine Wall5.050
Lower Large Intestine Wall7.676
Pancreas5.151
Skin1.111
Testes5.656
Prostate8.282
Thymus2.626
Thyroid1.414
Other Tissues2.020

Directions for Radiolabeling ProstaScint® (capromab pendetide) with Indium In 111 Chloride


Proper aseptic techniques and precautions for handling radioactive materials should be employed. Waterproof gloves should be worn during the radiolabeling procedure. The preparation of the product should be done by the following procedure.


  1. Required materials, not supplied:
    1. Indium In 111 Chloride from GE Healthcare, Inc. or Covidien, Inc.

    2. One sterile 1 mL syringe, one sterile 3 mL syringe

    3. Vial shield

    4. Dose calibrator set for Indium In 111

    5. Biodex Dark Green Chromatography strips

    6. Developing chamber for chromatography (e.g. scintillation vial)

    7. 21-23 gauge sterile needles

    8. Shield for 10 mL syringe

    9. Waterproof gloves

    10. Alcohol wipe

    11. Water-soluble marker

    12. 0.9% sodium chloride solution

    13. 0.05 M solution of diethylenetriamine pentaacetic acid (DTPA)

    14. Gamma ray detector


  2. Sterile, pyrogen-free Indium In 111 Chloride solution must be utilized in the preparation of the Indium In 111 ProstaScint®. The use of high purity Indium In 111 Chloride manufactured by GE Healthcare, Inc. or by Covidien, Inc. is required. The Indium In 111 Chloride should be used only to radiolabel ProstaScint® and should not be injected directly into the patient. The Indium In 111 Chloride should not be utilized after its expiration date.

  3. Before radiolabeling, bring the refrigerated ProstaScint® to room temperature. Note: ProstaScint® is a protein solution which may develop translucent particulates. These particulates will be removed by filtration.

  4. Clean the rubber stopper of each vial with an alcohol wipe. With a sterile 1 mL syringe add 0.1 mL of sodium acetate solution to the shielded vial of Indium In 111 chloride and mix. Retain remaining sodium acetate for use in Step 7.

  5. With the same 1 mL syringe, withdraw between 6 and 7 mCi of the buffered Indium In 111 chloride and add to the ProstaScint® vial. Flush the syringe to mix the preparation. Swirl gently to mix, and assay contents in a dose calibrator. On one of the labels provided, record the patient's identification, the date, time of preparation, and activity in the vial. Affix the label to the vial shield.

  6. Allow the labeling reaction to proceed at room temperature for 30 minutes.

  7. With a 3 mL syringe, add the remaining sodium acetate to the ProstaScint® reaction vial. To normalize pressure, withdraw an equal volume of air.

  8. Aseptically attach the 0.22 μm Millex® GV sterile filter (provided) and a sterile hypodermic needle to a 10 mL sterile disposable syringe and withdraw the contents of the reaction vial through the filter into the syringe. Keep the needle immersed in the solution to avoid creating an air-lock in the filter.

  9. Remove the filter and needle. Aseptically attach a fresh sterile hypodermic needle to the syringe. Assay syringe and contents in a dose calibrator. The syringe should contain not less than 4 mCi (148 MBq) of Indium In 111 ProstaScint®.

  10. Radiochemical purity (RCP) by Instant Thin Layer Chromatography (ITLC) can be determined by the following procedure:
    1. Mix equal parts (several drops of each) of Indium In 111 ProstaScint® (Capromab Penditide) with DTPA solution. Allow the mixture to stand at room temperature for one minute. Spot a small drop of the mixture onto an ITLC strip at its origin.

    2. Add 0.9% sodium chloride solution to the developing chamber to a depth of about 0.5 cm. Place the strip in a chromatography chamber with the origin at the bottom (ensure the strip does not bend or touch the walls of the chamber) and allow the solvent to migrate to about 0.5 cm from the end of the strip. A small dot made with a felt tip pen at this distance can help indicate the arrival of the solvent front. Remove from the chamber and cut the strip in half and measure the counts per minute (CPM) of both halves with a gamma ray detector.

    3. Calculate the percent RCP as follows:

      %RCP =              CPM bottom half              x 100

                      CPM bottom half + CPM top half

    4. If the radiochemical purity is <90%, the ITLC procedure should be repeated. If repeat testing remains <90%, the preparation should not be administered.


  11. On the second label provided in the kit, record the patient's identification, the date, time of assay, and activity in the syringe. Affix this label to the syringe shield.

  12. Indium In 111 ProstaScint® should be used within 8 hours of radiolabeling.

  13. Discard vials, needles, and syringes in accordance with local, state, and federal regulations governing radioactive and biohazardous waste.


Image Acquisition and Interpretation


Images should be acquired using a large field of view gamma camera equipped with a parallel hole medium energy collimator. The gamma camera should be calibrated using the 172 and 247 keV photopeaks for Indium In 111 with a 15-20% symmetric window.


Whole body or spot planar views of the pelvis, abdomen, and thorax should be performed between 72 and 120 hours following Indium In 111 ProstaScint® (capromab penditide) infusion. A cathartic is required the evening before imaging and a cleansing enema should be administered within an hour prior to each 72-120 hour imaging session. In addition, the bladder should be catheterized and irrigated.


Whole body acquisition should be carried out from skull through mid-femur. The total scan time over this area should be no less than 35 minutes using a 128x512 or 256x1024 matrix.


Planar images should be acquired in anterior and posterior views for 7.5 minutes per view using a 128x128 or 256x256 matrix. Due to uptake of Indium In 111 ProstaScint® by the liver, planar images obtained with the liver in the field of view must be acquired with adequate counts to allow the detection of lesions in the adjacent extrahepatic abdomen and pelvis. This may result in pixel overflow with image degradation in the region of the liver.


Two SPECT imaging sessions are necessary. The first SPECT session should be of the pelvis and be performed approximately 30 minutes after infusion to obtain a blood pool image. The second SPECT session should include both the pelvis and abdomen, including the lower liver margin through the prostatic fossa and be performed between 72 and 120 hours after infusion for detection of benign and malignant prostate tissue sites. Depending upon the capability of the camera field of view to include both pelvis and abdomen, either one or two separate acquisitions may be necessary during the second session.


To resolve imaging ambiguities possibly resulting from activity in blood pool, stool or urinary bladder, follow-up imaging sessions with full patient preparation should be performed.


The SPECT Images should be acquired using a 64x64 or 128x128 matrix for a minimum of 60 or 120 stops, respectively, over 360 degrees rotation for approximately 25 seconds per view at the first session and 50 seconds per view at the second session. Reconstruction should be performed using a Butterworth filter or equivalent in the transverse, coronal and sagittal views. An order of 5 and cut off of 0.5 may be used as a starting point. Slice thickness should be in the range of 6 to 12 mm.


Following Indium In 111 ProstaScint® (capromab penditide) administration, some of the radiolabel localizes in normal liver, spleen, bone marrow and genitalia.


It has been reported that Indium In 111 labeled antibodies may localize non-specifically in colostomy sites, degenerative joint disease, abdominal aneurysms, post-operative bowel adhesions, and local inflammatory lesions, including those typically associated with inflammatory bowel disease or secondary to surgery or radiation. Indium In 111 ProstaScint® can demonstrate apparent localization to sites of tortuous blood vessels. Careful review of the patient's medical history and other diagnostic information should aid in the interpretation of the images.


The diagnostic images acquired with Indium In 111 ProstaScint® should be interpreted in conjunction with other appropriate diagnostic tests.



HOW SUPPLIED


The ProstaScint® (capromab pendetide) kit (NDC No. 57902-817-01) for the preparation of Indium In 111 labeled Capromab Pendetide includes one vial containing 0.5 mg of ProstaScint® per 1 mL of sodium phosphate buffered saline and one 2 mL vial of sodium acetate solution, 0.5 M. These solutions are sterile and pyrogen free and contain no preservatives. Each kit also includes one sterile 0.22 μm Millex® GV filter, prescribing information, and two identification labels.



Storage


Store at 2° to 8°C (36° to 46°F). Do not freeze. Store upright.



REFERENCES


  1. Kocher, DC: Radioactive decay data tables. DOE/TIC 115:11026, 1981.

  2. Data supplied by Oak Ridge Associated Universities. Radiopharmaceutical Internal Dose Information Center, 1984.

  3. Wright, GL, Jr; et al. Expression of Prostate-Specific Membrane Antigen in Normal, Benign, and Malignant Prostate Tissues. Urol Oncol. 1995; 1:18-28.




EUSA Pharma (USA) Customer Service: (800) 833-3533


Manufactured by EUSA Pharma (USA), Inc.

Langhorne, PA 19047

License 1829


ProstaScint® is a registered trademark of

2010 EUSA Pharma (USA), Inc.


Printed in USA   606-0870A   Rev F

Revised 12/2010



PRINCIPAL DISPLAY PANEL


ProstaScint® Kit for the Preparation of Indium In 111 Capromab Pendetide (NDC 57902-817-01)


ProstaScint®

Kit for the Preparation of Indium In 111 Capromab Pendetide


EUSAPharma


Rx Only


A murine monoclonal antibody conjugate. Single dose. For intravenous administration only after preparation according to instructions. See enclosed insert.

Package contents (one adult unit-dose):

1 vial ProstaScint® (capromab pendetide) 0.5mg/mL (1mL)*, in PBS pH 6

1 vial Sodium Acetate Buffer Solution 0.5M (2mL)*

1 Millex® GV Filter (0.22μm)

1 Package insert with two identification labels.

*Refer to enclosed package insert for quantitative composition and directions for use.

Sterile and pyrogen-free. Contains no preservative.

Caution: Federal law prohibits dispensing without prescription.

No U.S. standard of potency.



 






ProstaScint KIT FOR THE PREPARATION OF INDIUM IN 111 CAPROMAB PENDETIDE 
capromab pendetide  kit






Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)57902-817










Packaging
#NDCPackage DescriptionMultilevel Packaging
157902-817-011 KIT In 1 BOXNone









QUANTITY OF PARTS
Part #Package QuantityTotal Product Quantity
Part 11 VIAL, SINGLE-DOSE  1 mL
Part 2

Convulsan




Convulsan may be available in the countries listed below.


Ingredient matches for Convulsan



Lamotrigine

Lamotrigine is reported as an ingredient of Convulsan in the following countries:


  • Russian Federation

International Drug Name Search